Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Ziopharm Oncology Reports Second Quarter 2018 Financial Results and Provides Corporate Update
Company Focused on Responding to FDA for Third-generation Trial NCI to file IND for Sleeping Beauty Manufactured TCR-T Cell Therapies Targeting Neoantigens in 4Q2018 Controlled IL-12 Monotherapy, Combination Studies Advancing Changes to Board of Directors and New Staff Illustrate Company Growth
View HTML
Toggle Summary Ziopharm Oncology Announces Changes to its Board of Directors
Scott Tarriff , CEO of Eagle Pharmaceuticals , Elected Lead Director Sir Murray Brennan , M.D., former U.S. Sen. Wyche Fowler to Step Down Paratek Pharmaceuticals CFO Doug Pag á n and Scholar Rock COO Elan Ezickson Nominated to Board Directors BOSTON , Aug.
View HTML
Toggle Summary Ziopharm Oncology to Announce Second Quarter 2018 Financial Results, Host Conference Call Aug. 8
BOSTON , July 31, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP) today announced that management will host a conference call and webcast slide presentation on Wednesday, Aug. 8 , at 4:30 p.m. ET to provide a corporate update and discuss financial results for the second quarter
View HTML
Toggle Summary Ziopharm Oncology Board Responds to Recent Stock Price Decline
-  Executing on clinical and business development with plans to add new Board members and expand management team   -  Annual meeting of stockholders is Sept. 18 BOSTON , July 26, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP), a biotechnology company focused on development of next
View HTML
Toggle Summary Ziopharm Oncology Enrolls First Patient in Phase 1 Trial Evaluating Combination Therapy of Controlled IL-12 and OPDIVO®
Phase 1 trial to evaluate Ad-RTS-hIL-12 plus veledimex in combination with nivolumab for treatment of recurrent glioblastoma BOSTON , June 28, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP), a biotechnology company focused on development of next generation immunotherapies utilizing
View HTML
Toggle Summary Ziopharm Oncology Reports on Status of Investigational New Drug Application for Phase 1 Trial to Evaluate CD19-targeted CAR T Therapy
BOSTON , June 18, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP) today announced the U.S. Food and Drug Administration ( FDA ) placed on clinical hold a Phase 1 trial to evaluate CD19-specific CAR-T therapies manufactured under point-of-care and requested additional information in
View HTML
Toggle Summary Ziopharm Oncology Presents Clinical Data Demonstrating Anti-tumor Immune Response of Controlled IL-12 Platform in Breast Cancer and Glioblastoma at American Society of Clinical Oncology (ASCO) Annual Meeting
- Ad-RTS-hIL-12 plus veledimex recruits T cells into breast and brain cancers - Median overall survival reaches 12.7 months in patients with recurrent glioblastoma in 20mg veledimex cohort who received Controlled IL-12 as a single agent - Over expression of immune checkpoint biomarkers demonstrated
View HTML
Toggle Summary Ziopharm Oncology to Present Data from Clinical Studies of Controlled IL-12 in Breast Cancer and Glioblastoma at American Society of Clinical Oncology (ASCO) Annual Meeting
-       Data from biopsies shows Ad-RTS-hIL-12 plus veledimex recruits killer T cells into breast and brain cancers -       IL-12 continues to demonstrate activity as a single-agent therapy, prolongs survival in patients with recurrent glioblastoma -       Results further support development of
View HTML
Toggle Summary Ziopharm Oncology Reports First Quarter 2018 Financial Results and Provides Corporate Update
-Expanding Controlled IL-12 platform to explore additional tumor types -Cash runway extended to 2Q 2019 with changes to Controlled IL-12 development plans -ASCO poster to detail IL-12 data in breast cancer, glioblastoma, highlight potential for combination with checkpoint inhibitors
View HTML
Toggle Summary Ziopharm Oncology to Announce First Quarter 2018 Financial Results, Host Conference Call May 10
BOSTON , May 02, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP), today announced that management will host a conference call and webcast slide presentation on Thursday, May 10 , at 4:30 p.m. ET to provide a corporate update and discuss financial results for the first quarter ended
View HTML